AZD-1305

DB11766InvestigationalSmall molecule

AZD1305 has been used in trials studying the treatment and basic science of Atrial Flutter, Atrial Fibrillation, and Left Ventricle Function.

Mechanism: Pharmacologically active on Voltage-gated inwardly rectifying potassium channel KCNH2, Sodium channel protein type 5 subunit alpha, and Voltage-dependent L-type calcium channel
Curator reviewed
Formula / weight: C₂₂H₃₁FN₄O₄ · 434.512 g/mol (avg)
Code names: AZD-1305

Resolves to

Compound

Structure

InChIKeyBLLNYXOLLAVTRF-HDICACEKSA-NSMILESCC(C)(C)OC(=O)NCCN1C[C@H]2CN(CCOC3=CC=C(C=C3F)C#N)C[C@@H](C1)O2

Targets

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with AZD-1305, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.